Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy by Moura, Daniela Silva et al.
Depression in Patients with Mastocytosis: Prevalence,
Features and Effects of Masitinib Therapy
Daniela Silva Moura
1,2, Serge Sultan
2,3, Sophie Georgin-Lavialle
1,4, Nathalie Pillet
5, Franc ¸ois
Montestruc
5, Paul Gineste
5, Ste ´phane Barete
6, Gandhi Damaj
7, Alain Moussy
5,8, Olivier Lortholary
9,
Olivier Hermine
1,4,5,8*
1Universite ´ Paris Descartes, Sorbonne, Paris Cite ´, Service d’he ´matologie, Centre de re ´fe ´rence des mastocytoses, Ho ˆpital Necker Enfants malades, Paris, France, 2Universite ´
Paris Descartes, Sorbonne, Paris Cite ´, Laboratoire de Psychopathologie et Processus de Sante ´ EA 4057, IUPDP Institut de Psychologie, Paris, France, 3Universite ´ de
Montre ´al, Centre de Recherche du CHU Sainte-Justine, Montre ´al, Canada, 4CNRS UMR 8147, Universite ´ Paris Descartes, Sorbonne, Paris Cite ´,H o ˆpital Necker-Enfants
malades, Paris, France, 5AB Science, S.A., Paris, France, 6De ´partement de dermatologie, Centre de re ´fe ´rence des mastocytoses, Ho ˆpital Tenon, Universite ´ Pierre et Marie
Curie, Paris, France, 7Service d’he ´matologie, CHU d’Amiens, Universite ´ Jules–Vernes Picardie, Amiens, France, 8Association Franc ¸aise pour les initiatives et la recherche
sur les mastocytes et les mastocytoses (AFIRMM), Paris, France, 9Universite ´ Paris Descartes, Sorbonne, Paris Cite ´, Service de maladies infectieuses et tropicales, Centre de
re ´fe ´rence des mastocytoses, Ho ˆpital Necker Enfants malades, Paris, France
Abstract
Depression in patients with mastocytosis is often reported but its prevalence and characteristics are not precisely described.
In addition, the impact of therapies targeting mast cells proliferation, differentiation and degranulation on psychic
symptoms of depression have never been investigated. Our objective was to determine the prevalence and to describe
features of depression in a large cohort of mastocytosis patients (n=288) and to investigate the therapeutic impact of the
protein kinase inhibitor masitinib in depression symptoms. The description of depression was based on the analysis of a
database with Hamilton scores using Principal Component Analysis (PCA). Efficacy of masitinib therapy was evaluated using
non parametric Wilcoxon test for paired data within a three months period (n=35). Our results show that patients with
indolent mastocytosis present an elevated prevalence of depression (64%). Depression was moderate in 56% but severe in
8% of cases. Core symptoms (such as psychic anxiety, depressed mood, work and interests) characterized depression in
mastocytosis patients. Masitinib therapy was associated with significant improvement (67% of the cases) of overall
depression, with 75% of recovery cases. Global Quality of Life slightly improved after masitinib therapy and did not
predicted depression improvement. In conclusion, depression is very frequent in mastocytosis patients and masitinib
therapy is associated with the reduction its psychic experiences. We conclude that depression in mastocytosis may originate
from processes related to mast cells activation. Masitinib could therefore be a useful treatment for mastocytosis patients
with depression and anxiety symptoms.
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Introduction
Mastocytosis is a rare disease characterized by mast cells (MC)
accumulation in one or several organs [1–3]. Based on organ
dysfunction, systemic mastocytosis is divided into indolent and
aggressive disease [1,4,5]. In the majority of cases (.90%)
mastocytosis presents as an indolent disease [6]. Even though
mastocytosis is usually not a life threatening disease, indolent forms
are associated with significant disability in more than 60% of
patients [7]. As such, it can have a significant negative impact on
quality of life.
Stem cell factor (SCF) is a growth factor that stimulates the
proliferation, the survival and the development of mast cells [8].
The biological activity of SCF is induced following its binding to its
receptor (SCF-R) encoded by the c-kit proto-oncogene. SCF-R/
KIT (also called CD117) is a member of the type III receptor
protein-tyrosine kinase family (TKR) [9]. Type III TKRs consist
of a glycosylated extra-cellular ligand-binding domain followed by
a transmembrane and a cytoplasmic domain which provides
docking sites for adaptor proteins following receptor activation
allowing cell signalling [10]. Gain of function mutations in c-kit
result in constitutive KIT activation and are related to mastocy-
tosis but also other neoplastic transformations including leukae-
mias, melanoma and others types of cancer [11,12]. These
mutations induce constitutive receptor autophosphorylation and
its ligand-independent activity [13]. In most of adult forms of
indolent systemic mastocytosis, KIT is constitutively activated as a
consequence of D816V mutation, whereas in pediatric forms of
mastocytosis extracellular and juxtamembrane mutations are more
common [14,15].
Treatment of mastocytosis is mainly symptomatic, except in
aggressive and systemic forms with severe disabling symptoms.
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26375Masitinib is a phenylaminothiazole-type tyrosine kinase inhibitor
that selectively targets KIT, platelet-derived growth factor
receptor (PDGFR) and Lyn kinase [16]. Masitinib’s inhibitory
effect results in cell cycle arrest and apoptosis of cell lines
dependent on KIT signaling [17]. In addition, masitinib inhibits
constitutive activation of KIT as a result of juxtamembrane and
extracellular mutations found in pediatric forms of mastocytosis. In
contrast, activation of KIT as a consequence of D816V mutation
is not inhibited by masitinib. However, by blocking Lyn masitinib
may block mast cell degranulation and therefore improve
symptoms related to mast cell degranulation. Thus, masitinib
may have a cytotoxic effect and may reduce tumor burden in
patients bearing pediatric’s type mutations or wild type c-kit [16].
Although some reported cases of systemic mastocytosis with
neurologic manifestations (neurosensory deafness, loss of con-
sciousness, encephalopathy, hypoxic lesions leading to Parkinson-
ism), suggest central nervous system involvement, it is unsure
whether it can be attributed to mast cell infiltration and/or
mediators releasing [18–21]. Masitinib is a tyrosine kinase
inhibitor (TKI) with exhibiting high affinity and selectivity in-vitro
for KIT receptor and efficiency in vivo, because this molecule has
been successfully tested in symptomatic patients with systemic
mastocytosis [16,22–24]. A phase 2a, multicenter open-label trial
over 12 weeks using masitinib showed a strong impact reducing
depression by 43% as compared with baseline [24]. This
unexpected effect conveyed physician’s attention to the links
between physiopathological mechanisms inhibited by masitinib
and depression in mastocytosis. Masitinib decreases mast cells
burden and tryptase levels and may influence depression through
mechanisms associated to one of these aspects.
Patients with mastocytosis present many psychopathological
manifestations. These manifestations are mainly characterized by
cognitive impairment (low attention span, difficulty concentrating
and forgetfulness) and negative emotionality (depression, poor
motivation, susceptibility to stress, irritability and anxiety).
Depression seems to be the most common (sometimes the major)
complaint among patients with mastocytosis and it has a profound
impact in current professional, social and emotional life.
Prevalence rates of depression among these patients range from
40% to 70% [7,25], whereas prevalence rate is around 7% in the
general population and 10%–50% in clinical samples with
advanced chronic condition such as cancer or 14%–25% in
advanced diabetes [26–30]. In addition, recent research in
mastocytosis has found dissociation between the objective illness
physical impact and depression suggesting that core aspects of
depression in this condition are not secondary to the consequence
of physical involvement but more a primitive feature of the disease
[7].
One of the instruments commonly used to identify depression in
patients in clinical trials (including those with mastocytosis) is the
17 items Hamilton Depression Scale (Ham-D17). However, the
difficulty in using Ham-D17 to assess depression in mastocytosis
may reside in the fact that patients frequently present a vast
number of somatic symptoms including insomnia, muscular pain,
headache, flush or gastro-intestinal disorders which could in some
cases match with Ham-D17 items. Thus, mastocytosis patients
presenting a large amount of somatic manifestations could have a
high score in Ham-D17 without actually presenting core
symptoms of depression such as depressive mood, psychic anxiety,
psychomotor retardation or guilt. This means that when exploring
depression and treatment effects in mastocytosis we first need to
consider the core components of depressive symptoms. That is the
reason why we first wanted to describe depression, its structure
and symptoms in a large cohort of patients with mastocytosis.
Secondarily, we intended to explore changes in depression
components and symptoms following a masitinib treatment used
to reduce clinical symptoms of mastocytosis.
Results
Features and prevalence of depression in mastocytosis
patients (N=288)
The prevalence rate of mild-moderate depression (Ham-D17
scores $ 8 and #22) in our sample (67% females; mean age=47;
standard deviation (S.D.) =13.58) was 56% and severe depression
(Ham-D17 scores $23) was observed in 8% of cases (n=23). In
order to know which Ham-D symptoms were mostly prevalent in
the sample we analyzed the frequency of patients reporting scores
$ 2 according to the severity of depression (Fig. 1). Patients
presenting severe depression differed significantly from those
presenting mild-moderate depression in all items scored $ 2
(p#0.005) except the following: middle insomnia which was very
prevalent in both groups (37%–48% respectively), psychomotor
retardation, gastrointestinal symptoms and loss of weight which
were rare in both groups (2%–3%). Severe depression was
characterized by a very high prevalence of impairment in work
and activities (97%), depressed mood (95%), somatic anxiety (83%)
and guilt (61%). Genital symptoms (56%), early insomnia (39%)
and suicide ideation (30%) were also very regular. General somatic
symptoms (22%), psychic anxiety (21%) and hypochondriasis
(16%) were less common in this group. Others symptoms were
rare or only slightly present (less than 13%). When comparing
these groups, patients with mild-moderate depression presented
significantly (p#0.0005) more late insomnia (22%), agitation
(37%), psychic anxiety (44%) and hypochondriasis (34%).
Depression in mastocytosis is composed by psychic
depression symptoms and sleep disturbances
The Ham-D17 items of the final sample (N=288) were
submitted to a first Principal Component Analyses (PCA) and a
promax rotation with a power of 4. Two stable components were
found explaining 36.4% of the overall variance (27.96% and
8.38% respectively). Items with loadings under 0.40 were
considered lacking sufficient explanation and were excluded from
the dimensions. These two components were moderately corre-
lated (r=0.48). Based on this first PCA and excluding for items
suicide and insight which had insufficient loadings, a two-factor
solution appeared with a first dimension (items: depressed mood,
feelings of guilt, work and activities impairment, psychomotor
retardation, agitation, psychic anxiety, somatic anxiety, general
somatic symptoms, genital symptoms and hypochondriasis)
including most of the core symptoms of depression along with a
dimension representing sleep and gastrointestinal disturbances
(items: early, middle and late insomnia, gastrointestinal symptoms
and loss of weight). To ascertain the consistency of these
dimensions, we analyzed inter-item correlations and item-total
correlations in each. In the first dimension most inter-item
correlations ranged between 0.41 and 0.53. In the second
dimension, only middle and late insomnia were correlated with
correlations superior to 0.40 (r=0.45; p,0.001). The following
items had correlations under 0.40: early insomnia, psychomotor
retardation, agitation, genital and gastrointestinal symptoms,
hypochondriasis, loss of weight and loss of insight.
Based on the study of these correlations, we performed a second
PCA with a promax rotation and a power of 4 including only the
items with inter-item correlations exceeding 0.40 (depressed mood,
guilt, middle and late insomnia, psychic and somatic anxiety, work
and interests impairment and general somatic symptoms). This
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(41.4% and 13.15% respectively) of the overall variance and
moderately correlated (r=0.42). The first dimension included the
psychic symptoms of depression: depressed mood, guilt, work and
activities impairment and anxiety (psychic and somatic). We called
this dimension ‘‘Anxious-depression’’. The second dimension
included the items middle and late insomnia and was called
‘‘Sleep disturbances’’ (Table 1). The correlation between this
version of the scale and the 17 items version was 0.95 (p,0.001).
Based on these results further investigations were done on these
two components in addition to the traditional Ham-D17 items and
score.
Depression improved following masitinib therapy
At the beginning of the trial (week 0) among 35 patients, 69%
presented mild-moderate (n=22, 92%) or severe (n=2, 8%)
depression. At the end (week 12), only one initially non depressed
patient presented a mild depression score (Ham-D17=14) and 8
(33%) of the baseline depressed patients did not present any
improvement (Table S1). Depression improvement was considered
as a reduction of at least 20% of the initial score [31]. Changes in
depression scores were significant (p=0.0001, d=0.63) and
depression improvement concerned 67% (n=16) of the cases
(Fig. 2A). Among improved patients, 75% (n=12) presented
remission as defined by a score #7 [32]. Mean scores in anxious
depression and sleep disturbances dimensions were also signifi-
cantly reduced after masitinib therapy (p=0.0004, d=0.52 and
p=0.0112, d=0.41 respectively) (Fig. 2B/C). In order to provide
data comparable with pharmacological studies analyzing classical
depression treatment response as with fluoxetine we tested
response rate using similar depression baseline cut-point of
Ham-D17$16 and a decrease of at least 50% in final score to
consider response to masitinib. Using these criteria, 8 patients
Figure 1. Symptoms of depression from the Ham-D17 in non depressed, mild-moderate and severe depressed patients with
mastocytosis. Chi square test was performed to compare groups item by item. Severe depression was characterized by a huge prevalence of
impairment in work and activities (97%), depressed mood (95%), somatic anxiety (83%), guilt (61%) and genital symptoms (56%). Mild-moderate
depression was characterized by a higher prevalence of late insomnia (22%), agitation (37%), psychic anxiety (44%) and hypochondriasis (34%).
doi:10.1371/journal.pone.0026375.g001
Table 1. Factor loadings after promax rotation.
Hamilton depression
items Dimensions
anxious-depression
Sleep
disturbances
depressed mood 0.755 0.121
Guilt 0.657 0.151
work and activities 0.677 0.248
psychic anxiety 0.681 0.235
somatic anxiety 0.686 0.070
general somatic symptoms 0.610 0.121
middle insomnia 0.191 0.819
late insomnia 0.158 0.832
Two components solution explaining 54% of the overall variance and
moderately correlated (r=.46) after exclusion of items with correlation loadings
under .40. ‘‘Anxious-depression’’ dimension included the following items:
depressed mood, guilt, work and activities and anxiety (psychic and somatic).
‘‘Sleep disturbances’’ dimension included the items middle and late insomnia.
The Keiser-Meyer-Olkin measure of sampling adequacy revealed a score of 0.85
confirming the adequacy of the data for factor analysis.
doi:10.1371/journal.pone.0026375.t001
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was 50% and 25% displayed a remission score of HAM-D #7( 2
patients) (Table S1).
Depression improvement after masitinib therapy was not
related to improvements in global quality of life
In order to know whether improvement of depression after
masitinib therapy could be attributed to global quality of life
(gQoL) improvement we investigated the relations between these
evolutions. Global quality of life levels (mean week0 =47.20; S.D.
=21.64, mean week12=58.35; S.D. =20.73) slightly improved
after mastinib therapy (p=0.043, d=0.53). Improvement in
gQoL (defined as an increase of at least 20% in score) concerned
43% (n=15) of patients; 17% (n=6) were worsened and 40%
(n=14) did not display any changes. Among improved patients,
only 4 presented an increase of at least 50% in gQoL scores.
Baseline gQoL scores were negatively correlated to baseline scores
in depression showing that a better global quality of life was related
to lower depression scores at baseline (r= 20.471; p=0.004). At
the end of the trial, global gQoL was not correlated to depression
scores (total and dimensions) (r=0.077 to 20.287; ns). We
computed relative change indices by dividing absolute raw
changes by baseline raw values. Relative changes in gQoL were
unrelated to relative changes in depression scores (r=20.041;
p=0.815).
Discussion
In the present study we found in a sample of 288 patients with
mastocytosis a high prevalence of depression (64%) and a
significant improvement of depression following masitinib therapy.
Depression is a frequent comorbidity among patients with
physical illness and it is associated to increased disability [33]. In
this work we showed that patients with systemic indolent
mastocytosis present an elevated prevalence of depression (64%)
confirming and extending results from previous studies [7,25].
However, this study was the first to evaluate the severity of
depression in these patients. Our results show that depression in
mastocytosis is mainly (56% of the cases) moderate whereas severe
depression concerned 8% of depressed patients. This high
prevalence is surprising because indolent forms of mastocytosis
are not life threatening as is cancer and yet, depression prevalence
rates are comparable or even higher than in this latter condition
[26–28,30].
We showed that depression among mastocytosis patients was
predominantly characterized by anxious and depressive symp-
toms. Physical symptoms as gastrointestinal complaints, general
symptoms and loss of weight were only slightly present in
mastocytosis depressed patients. This suggests that depression
among patients presenting indolent forms of the disease is rarely
accompanied by appetite loss or anorexia. Consequently, ‘loss of
weight’ was rarely scored. More surprising was the low prevalence
of general somatic symptoms as they reflect pain (cephalic,
muscular or articular) suggesting that these symptoms are often
related to mastocytosis but not as much to depression among these
patients. Psychomotor retardation and loss of insight were rare and
Figure 2. Depression improvement following masitinib thera-
py. A. Mean total score in depression reduced significantly at the end of
the trial (p=.0001); pre-mean Ham-D17=11.23 (S.D.=6.8); post-mean
Ham-D17=6.97 (S.D.=6.9). B. Mean score in sleep disturbances
dimension reduced significantly at the end of the trial (p=.0112); pre-
mean Ham-D17=1.57 (S.D.=1.5); post-mean Ham-D17=1.00
(S.D.=1.3). C. Mean score in anxious depression dimension reduced
significantly at the end of the trial (p=.0004); pre-mean Ham-D17=5.83
(S.D.=4.0); post-mean Ham-D17=3.77 (S.D.=3.9). + Exclusion of this
patient from the analysis did not change the results. * (p#0.05); **
(p#0.0005); *** (p#0.0001).
doi:10.1371/journal.pone.0026375.g002
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Interestingly, hypochondriasis was more prevalent among mild-
moderate depressed patients while genital complaints were more
prevalent among severe depressed patients. This result suggests
that severe depressed patients with mastocytosis are less concerned
or at least less apprehensive about their bodily sensations and
health state than mild-moderate depressed patients but are more
impaired in sexuality.
Only 8% of patients presented a severe depression score.
However, as might be expected, these severely depressed patients
displayed a high frequency (30%–95%) of guilt, suicidal ideation
and depressed mood. The high frequency of this group of
symptoms is a warning for a risk of suicidal attempt that should be
more seriously taken into account in severe depressed patients with
mastocytosis as it is in people with other conditions. Our results
suggest that depression in mastocytosis has a specific pattern
different from those in other physical conditions. For example, in
advanced diabetes, depression is characterized by cognitive/
affective symptoms [34]. These very same symptoms were also
associated with cardiovascular prognosis in patients with post-
myocardial infarction [35]. In mastocytosis, depression does not
seem to be related to physical related symptoms or severity and
therefore should be considered as an endogenous manifestation.
In this study, we evaluated the response to masitinib without
placebo condition among a cohort from an open-label trial.
Indeed, masitinib is a tyrosine kinase inhibitor with a specific
action on MC [16,22–24]. Masitinib has already showed efficacy
in the treatment of cutaneous mastocytosis [24]. Although in this
study a placebo control was absent, our results showed impressive
response rates for masitinib therapy on depression associated with
mastocytosis. Masitinib treatment was associated with significant
improvement in depression (67% of responders and 75% of
remitted patients among responders). We also used different
criteria for depression (Ham-D17$16) and response (a decrease of
at least 50% of scores in Ham-D17) and found a response rate of
50% and a remission rate of 25%. As a comparison, fluoxetine, a
widely used antidepressant drug, has been associated with a
response rate of 60% and a remission rate of 58% after 10 weeks of
treatment in a sample of patients without mastocytosis, but with
comparable baseline depression levels and same criteria for
response [36]. These results bring evidence to anti-depressant
effects of masitinib in the context of mastocytosis. However, more
research is needed to confirm masitinib efficacy on depression
using controlled trials and larger samples.
Quality of life in mastocytosis is often impaired because of the
chronicity of some symptoms but most patients do not experience
severe functional disabling. In our previous work we have shown
that the impact of mastocytosis symptoms in quality of life was
related to the patients’ subjective perception of their own
symptoms [7]. The masitinib efficacy in bringing relief to physical
and clinical symptoms of mastocytosis has been demonstrated
[24]. It has been shown in cancer or diabetic patients that poor
quality of life is related to symptoms of depression and anxiety
[29]. Therefore, we wanted to explore effects of masitinib in
depression and if they were independent of gQoL. We showed that
despite a relation between a deteriorated quality of life and
depression at baseline, improvements in gQoL did not explain
improvements in depression after masitinib therapy. This last
result suggests that depression in mastocytosis does not improves in
relation to a better QoL. This result is in line with our hypothesis
that depression in mastocytosis represents a systemic neurological
manifestation of the disease besides other physical symptoms.
Instead, it suggests that improvements in depression could be
influenced by the inhibitory effect of masitinib on mast cells
activation and cerebral dysfunction underlining the systemic
nature of depression in this condition. This strongly suggest that
depression in mastocytosis is a primary systemic symptom of the
disease rather than only a secondary psychological distress reaction
and that masitinib could reduce neuropsychological symptoms by
specifically targeting MC degranulation and migration.
We suggest that the configuration of depression in mastocytosis
could be articulated into two dimensions: i. an ‘‘anxious-
depression dimension’’ including the symptoms reflecting core
cognitive, affective and somatic aspects of depression (depressed
mood, guilt, work and interests impairments) and anxiety (somatic
and psychic anxiety), and ii. a ‘‘sleep disturbances dimension’’
grouping sleep disturbances related to depression (middle and late
insomnia). When exploring depression in mastocytosis, symptoms
usually considered as the core of depression (psychic anxiety,
depressed mood, work and interests) characterized depressed
patients. In a subsample of 35 patients, Masitinib therapy was
associated with significant improvement (50%–67% of the cases) of
overall depression, with 25%–75% of recovery cases according to
criteria for baseline depression and improvement. Response in
depression symptoms after masitinib therapy was demonstrated
through improvement of the anxious-depression dimension as well
as of total scores. Global quality of life slightly improved after
masitinib therapy but these changes did not predict depression
improvement. These results suggest a specific MC involvement in
psychological symptoms present in this disease.
This huge prevalence of depression suggests a systemic brain
involvement probably through MC mediators such as serotonin,
substance P or cytokines. Recent research suggested that mast cells
are involved in mechanisms related to emotion regulation [37–39].
Mast cells are often located around vessels and it has been shown
that, even if mast cells do not cross the blood-brain-barrier (BBB),
these cells can be implicated in inflammatory process through
mediators releasing that will increase permeability of the BBB [40–
44]. Indeed, MC are involved in many other diseases including
neuroinflammatory conditions such as irritable bowel syndrome,
multiple sclerosis, asthma, atopic dermatitis, fibromyalgia, mi-
graine, rheumatoid arthritis, scleroderma, etc [45]. In these
conditions, negative emotionality such as anxiety is also common
among patients [37]. This relation between MC and negative
emotions (i.e. anxiety) has also been demonstrated in rodents
suggesting a conservation of this relation through evolution and an
involvement of MC in aspects of emotionality [39]. The presence
of MC in brain regions; at the proximity of nerves and vessels,
could sign a primary MC involvement in neurobiological
determinants of depression [39,46–48]. In the brain, many MC
reside also in the thalamus [49–55]. Lesions or stimulation of the
thalamus (medial dorsal and anterior nuclei) are associated with
changes in emotional reactivity [53–55]. In addition, the
regulation of emotional behavior is due to the connections of the
nuclei of thalamus with other limbic system structures [56,57]. We
could hypothesize that masitinib could reduce depression
symptoms in mastocytosis by two pathways: i. by blocking
mediators secreted by mast cells involved in increasing perme-
ability of the BBB and brain inflammation; ii. by reducing mast
cells numbers in the thalamus or other structures of the limbic
system through its direct effect on KIT and Lyn.
In this study we have analysed data from cohort of patients
derived from a multicenter, open-label phase 1a and phase 2a
trial. Therefore there was no group of patients with mastocytosis
displaying depression which were not treated by masitinib to show
that in this case depression scores remains stable between baseline
and the end of the study. Secondly, although we used a validated
measure of depression, this is not a structured diagnostic interview,
Mastocytosis, Depression and Masitinib Therapy
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depression. Further research should address these limitations and
explore the link between MC and psychological manifestations,
such as depression and anxiety in mast cell related diseases.
In conclusion, our results suggest that depression in mastocytosis
may share common underlying processes related to the disease
and/or MC Our results suggest that a pharmacological interven-
tion, specifically targeting MC, alone brought a satisfactory
improvement of depression. As it has been evidenced in other
conditions such as obesity and diabetes, a systemic origin common
to mastocytosis and depression could be searched for. In diabetes
for example, a large part of depression has been suggested to be
systemic rather than secondary because both conditions have been
related to common underlying biological processes including
inflammation processes [58,59]. This may also be applicable to
mastocytosis and would explain why we observe such a dramatic
decrease of depression following masitinib. Furthermore, brain
mast cells have been shown to evoke hypothalamic-pituitary-
adrenal responses via centrally released histamine and corticotro-
phin-releasing factor [51]. Also, the hypersecretion of cortisol and
the dysfunction of the hypothalamo-pituitary-adrenal axis seem to
be implicated in medical co-morbidities associated with mood
disorder [60]. The results underline the fact that masitinib not only
affect mastocytosis physical symptoms as it has been shown [24],
but also that it seem to favourably impact depression and anxiety
symptoms, by targeting specifically MC.
Methods
Sample description (Table 2)
We analyzed a database containing Ham-D17 scores for 288
patients identified by the Association Franc ¸aise pour les Initiatives
et Recherche sur les Mastocytes et la Mastocytose (AFIRMM) and
tested between 2003 and 2007. All patients had a proven diagnosis
of mastocytosis following the WHO criteria [61]. From this large
sample, 35 patients were included in a pharmacotherapeutical
phase 1a (n=25) and phase 2a (n=25) multicenter, open-label
trial to evaluate the response to masitinib in indolent mastocytosis
with handicap, with a 3-month interval between the baseline (week
0) and final (week 12) tests [24]. We retained for our study only
patients with complete measures in week 0 and week 12, thus 15
patients were excluded.
Measures
In the whole sample (N=288), the following measures were
available: age, gender, Hamilton scores (Table 2). With the
exception of age, missing data represented less than 10% in this
sample and an imputation was not necessary. In the follow-up
study (masitinib protocols), additional measures of quality of life
were taken (measured with the cancer quality of life questionnaire
(EORTC-QLQ-C30 version 3).
The Hamilton Depression Scale. The Ham-D17 has been
mainly used to assess depression in clinical trials and remains a
reference measure to evaluate depression in research concerning
somatic patients [62]. Ham-D17 is composed of 17 items scored 0-
4 (depressed mood, guilt, suicide, psychic and somatic anxiety,
psychomotor retardation, agitation, hypochondriasis, work and
interests impairment) or 0–2 (early, middle and late insomnia,
gastrointestinal, somatic general, genital, loss of weight and loss of
insight items) according to the absence, presence and seriousness
of the symptom. These items reflect two groups of symptoms: core
symptoms of depression (depressed mood, guilt, work and interests
impairment, psychic anxiety, psychomotor retardation and general
somatic symptoms) and symptoms reflecting secondary aspects and
related to cognitive (hypochondriasis, suicide thoughts, loss of
insight, agitation), and somatic disturbances (somatic anxiety,
gastrointestinal symptoms, genital symptoms, loss of weight, early,
middle and late insomnia) [63,64]. The total score of Ham-D17 is
usually used as criterion to appreciate effect of treatment in clinical
trials. However, the primary efficacy criterion should focus on the
total score of core symptoms since they reflect the clinical response
related to more typical aspects of depression [65]. Although the
Ham-D17 was not initially designed as a self-report, Reynolds and
Kobak developed a paper and pencil version with 17 items
corresponding in contents and scoring to the standard Ham-D17
version and which showed excellent reliability [66].
Quality of life questionnaire. The European Organisation
for Research and Treatment of Cancer Quality of Life Core
Questionnaire (EORTC-QLQC30) is a cancer specific
questionnaire, reporting health related quality of life in these
patients [67]. It is a 30 item self-report instrument with Likert
response scales whereby increasing scores indicate increasing
burden for the functional and symptom scales. The questionnaire
provides a quality of life ‘‘global score’’ (gQoL)’’ were an increased
score indicates a good level of quality of life in addition to the
functional and the symptoms scales.
Procedures
The study was approved by the local ethical committee of
Necker hospital, patients were given informed consents and the
study was carried out in compliance with the precepts of the
Helsinki protocol. Data were collected through a mail-back
Table 2. Sample description.
Afirmm protocol (N=288)
Gender 98 men/163 women
Age in years (S.D.) – (range) 47 (13.58) – (20–82)
Ham-D17 total score (S.D.) – (range) 11.4 (7.7) – (0–35)
Masitinib trial (N=35)
Gender 11 men/24 women
Age in years (S.D.) – (range) 49 (12.74) – (19–77)
Ham-D17 total score week 0 (S.D.) – (range) 11.23 (6.89) – (0–28)
Ham-D17 total score week 12 (S.D.) – (range) 6.97 (6.90) – (0–32)
S.D: standard deviation; Ham-D17: Hamilton depression scale-17 items.
doi:10.1371/journal.pone.0026375.t002
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filled questionnaires within a week. For the follow-up subsample
(protocols), patients were interviewed at baseline and at week 12
by a trained clinician.
Statistical analysis
SPSS version 17.0 0 (IBM SPSS Inc., Chicago, IL, USA) was
used for most analysis. Wilcoxon and Chi-squared tests were
performed using GraphPad Prism software version 5.01 (Graph-
Pad Software Inc., San Diego, CA). To describe depression, we
explored the structure of the Ham-D17 using Principal Compo-
nent Analyses (PCA) and Chi-square tests. To explore the effect of
therapy on depression symptoms, we compared pre-post scores
and items using non parametric Wilcoxon test for paired data. To
investigate the effects of quality of life on depression improvement
after masitinib, we used correlation and linear regression. All
reported p values are two tailed with a significance level of .05.
Supporting Information
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